Please note the ANZCTR will be unattended from Friday 24 December 2021 for the holidays. The Registry will re-open on Monday 17 January 2022. Submissions and updates will not be processed during that time.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
Safety and Effectiveness of the AcuFocus Corneal Inlay ACI7000PDT in Presbyopes
Scientific title
A Prospective Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the AcuFocus Corneal Inlay ACI 7000PDT Implanted Intrastromally for Modified Monovision in Presbyopic Subjects
Secondary ID [1] 0 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Presbyopia 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Study type
Description of intervention(s) / exposure
Treatment: Devices - AcuFocus Corneal Inlay ACI 7000PDT

Experimental: AcuFocus Corneal Inlay - The AcuFocus Corneal Inlay ACI 7000PDT, which is a small medical device, will be surgically implanted in one eye of each subject.

Treatment: Devices: AcuFocus Corneal Inlay ACI 7000PDT
corneal inlay

Intervention code [1] 0 0
Treatment: Devices
Comparator / control treatment
Control group

Primary outcome [1] 0 0
Uncorrected Near Visual Acuity 20/32 or Better
Timepoint [1] 0 0
12 months
Secondary outcome [1] 0 0
Subjective Rating of Near Visual Acuity at 12 Months as Measured by Subjective Questionnaire - Mean subjective rating via questionnaire on 1 to 7 rating scale (1= very dissatisfied and 7 = very satisfied).
Timepoint [1] 0 0
12 months

Key inclusion criteria
1. Subjects must sign and be given a copy of the written Informed Consent form.

2. Subjects must be emmetropes needing a magnitude of +1.00D to +2.50D of reading add.

3. Subjects must have distance corrected near visual acuity worse than 20/40 and better
than 20/100 in the eye to be implanted.

4. Subjects must have distance visual acuity correctable to at least 20/20 in both eyes.

5. Subjects must have a preoperative spherical equivalent of plano defined as Plano to
-0.75D with no more than 0.75D of refractive cylinder as determined by cycloplegic
refraction in the eye to be implanted.

6. Subjects must have a stable refraction twelve months prior to ACI implantation: i.e.
MRSE within 0.50D over prior twelve months as determined by subject history.

7. Subjects who are soft contact lens wearers must discontinue their contact lenses for
at least one week prior to ACI pre-operative examination.

8. Subjects must have a minimum central corneal thickness of = 500 microns in the eye to
be implanted.

9. Subjects must have a corneal power of = 41.00D and = 47.00D in all meridians in the
eye to be implanted.

10. Subjects must be = 45 years and = 60 years of age at the time of subject eligibility

11. Subjects must have an endothelial cell count = 2000 cells/mm2 in the eye to be

12. Subjects must be willing and able to return for scheduled follow-up examinations for
12 months after surgery.

13. Subjects must demonstrate tolerance to monovision blur in the eye to be implanted as
determined by loose lens blur tolerance or monovision contact lens trial.
Minimum age
45 Years
Maximum age
60 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
1. Subjects with a difference of >1.00D between the spherical equivalent manifest
refraction and the spherical equivalent cycloplegic refraction.

2. Subjects with anterior segment pathology, including cataracts, in the eye to be

3. Subjects with residual, recurrent, active ocular or uncontrolled eyelid disease, or
any corneal abnormality (including endothelial dystrophy, guttata, recurrent corneal
erosion, etc.) in the eye to be implanted.

4. Subjects with ophthalmoscopic or topographic signs of keratoconus (or keratoconus
suspect) or keratoectasia in the eye to be implanted.

5. Subjects with dry eye as determined by objective testing; anesthetized Schirmer's test
result <10 mm or a tear break-up time (TBUT) less than 10 seconds are excluded.

6. Subjects taking chronic systemic medications known to exacerbate or induce moderate to
severe dry eye in so far as measures of TBUT and Schirmers are decreased or borderline
per Exclusion Criterion #5. Subjects taking the following classes of medications
should be evaluated: anti-depressants, anti-histamines, beta-blockers, phenothiazines,
atropine and atropine derivatives, oral contraceptives, anxiolytics, diuretics,
anti-cholinergics, and anti-arrhythmics.

7. Subjects with distorted or unclear corneal mires on topography maps of the eye to be

8. Subjects with macular degeneration, retinal detachment, or any other fundus pathology
that would prevent an acceptable visual outcome in the eye to be implanted.

9. Subjects who have worn RGP or PMMA contact lenses within the last 6 months.

10. Subjects who have undergone previous intraocular or corneal surgery, including PRK,
LASIK, CK, LASEK, and cataract surgery in the eye to be implanted.

11. Subjects with a history of herpes zoster or herpes simplex keratitis.

12. Subjects who have a history of steroid-responsive rise in intraocular pressure,
preoperative IOP > 21 mmHg, glaucoma, ocular hypertension, or are glaucoma suspects.

13. Subjects with an abnormal threshold visual field.

14. Subjects with a history of diagnosed diabetes, diagnosed autoimmune disease,
connective tissue disease, or clinically significant atopic syndrome.

15. Subjects on chronic systemic corticosteroids or other immunosuppressive therapy that
may affect wound healing, and any immunocompromised subjects.

16. Subjects who are using ophthalmic medication(s) other than artificial tears for
treatment of any ocular pathology including ocular allergy.

17. Subjects using systemic medications with significant ocular side effects.

18. Subjects who are pregnant, lactating, or of child-bearing potential and not practicing
a medically approved method of birth control.

19. Subjects with known sensitivity to planned study concomitant medications.

20. Subjects who are participating in any other ophthalmic drug or device clinical trial
during the time of this clinical investigation.

Study design
Purpose of the study
Allocation to intervention
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Not Applicable
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Vision Eye Institute - Bondi Junction
Recruitment postcode(s) [1] 0 0
2022 - Bondi Junction
Recruitment outside Australia
Country [1] 0 0
State/province [1] 0 0
Country [2] 0 0
State/province [2] 0 0
Country [3] 0 0
State/province [3] 0 0
Country [4] 0 0
State/province [4] 0 0
Country [5] 0 0
New Zealand
State/province [5] 0 0
Country [6] 0 0
New Zealand
State/province [6] 0 0
Country [7] 0 0
State/province [7] 0 0
Makati City
Country [8] 0 0
State/province [8] 0 0
Country [9] 0 0
State/province [9] 0 0
Country [10] 0 0
State/province [10] 0 0

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
AcuFocus, Inc.

Ethics approval
Ethics application status

Brief summary
The purpose of this study is to determine if the AcuFocus Corneal Inlay ACI 7000PDT will
provide an effective method of for the correction of presbyopia in patients who have normal
distance vision but need correction such as glasses or contact lenses to see clearly at near.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 0 0
Perry Binder, MD
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
Other publications